The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness.
Gradientech's CEO said the financing round, which supports the development of its rapid antibiotic susceptibility system, indicates an increased awareness of sepsis.
Inflammatix said that if its test obtains Emergency Use Authorization next year, clinicians will be able to better gauge the severity of a COVID-19 patient's infection.
The collaboration in particular focuses on the UK market introduction of SphingoTec's point-of-care tests for use of novel biomarkers in critical care.
The firm is completing a clinical study that it hopes will facilitate the launch of its AST system that provides results in four hours after a positive blood culture.
